Posted by Michael Wonder on 10 Feb 2022
Eli Lilly promises 40% discount for Innovent’s PD-1 in last-ditch bid to shift FDA review to drug pricing
10 February 2022 - Eli Lilly has been talking up a “disruptive” pricing strategy for its Innovent Biologics partnered PD-1 inhibitor Tyvyt in the U.S. Now, we have an idea of what the company means. But whether it’s actually “disruptive?” That’s less clear.
Should the drug be approved, Lilly plans to offer an approximate 40% discount for Tyvyt’s wholesale acquisition cost compared with PD-1s already available on the U.S. market, a company spokesperson told Fierce Pharma. Existing PD-1s, led by Merck’s Keytruda, bear annual list prices above $150,000.
